Hart Biologicals is continuing to get supplies of its products to partners overseas, as the UK enters a further period of restrictions due to the coronavirus pandemic.
After the busy Easter period, shipments have successfully left the company’s UK manufacturing site to all parts of Europe, some Middle Eastern countries and North America.
Jennifer Feasby, Quality Manager at Hart Biologicals, said: “We are confident that with the measures we have put in place around the site and the great cooperation we have had from all of our staff, the essential work we carry out for the benefit of our patients and customers should continue uninterrupted.
“We have had to make some adjustments to the way we work to maintain compliance with the social distancing and safety guidelines recommended by the Government, however, so far disruption has been very limited.”
Jennifer and her department are responsible for ensuring that all products manufactured meet the appropriate quality and regulatory standards at all times.
Jennifer continued: “It is vital that we maintain supplies of our products to our business partners during these very difficult times. Many of the company’s products are essential and without these or services we provide, the lives and wellbeing of the patients we serve would be put at serious risk.”
Hart Biologicals provides products and services designed to prevent the risk of haemorrhage and thrombosis; and supports a network of organisations around the world to distribute its products. It also provides contract manufacturing services to a number of business partners across the continents.
The company is also extensively engaged in supplying custom-made products and services directly to a number of high-profile companies involved in the supply in-vitro diagnostics.
For the previous response in relation to COVID-19, please visit: https://www.hartbio.co.uk/news/hart-biologicals-continues-supply-nhs/
